PROTAC CDK4/6 degrader-2
PROTAC CDK4/6 degrader-2 is an orally active and selective PROTAC degrader that targets CDK4/6 degradation by recruiting cereblon. PROTAC CDK4/6 degrader-2 exhibits DC50 values of 10.9 nM and 9.6 nM for CDK4 and CDK6, respectively. PROTAC CDK4/6 degrader-2 inhibits RB phosphorylation and cell cycle progression. PROTAC CDK4/6 degrader-2 is applicable for research on breast cancer and CDK4/6 inhibitor resistance.
(Pink: CDK4 and CDK6 ligand (HY-114338); Blue: Cereblon ligand (HY-14658); Black: linker).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 3135520-67-8
- Formule: C47H54N10O6
- Masse moléculaire:855.00
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Voir tous les produits spécifiques à Isoform PROTACs
More
Activité biologique
Description
IC50 & Target
[1]|
CDK4 10.9 nM (DC50) |
CDK6 9.6 nM (DC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MCF7 | GI50 |
10.09 nM
|
Antiproliferative activity against human MCF-7 breast cancer cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay.
Antiproliferative activity against human MCF-7 breast cancer cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay.
|
42628378 |
| T47D | GI50 |
72.02 nM
|
Antiproliferative activity against human T47D breast cancer cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay.
Antiproliferative activity against human T47D breast cancer cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay.
|
42628378 |
| MCF-10A | GI50 |
8.687 μM
|
Cytotoxicity against normal human MCF-10A breast cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay.
Cytotoxicity against normal human MCF-10A breast cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay.
|
42628378 |
In Vitro
PROTAC CDK4/6 degrader-2 (compound P11) (1.2-300 nM; 24 h) dose-dependently degrades CDK4 and CDK6 in MCF-7 cells with DC50 values of 10.9 nM and 9.6 nM, respectively; treatment at 50 nM for 24 h results in 75% degradation of CDK4[1].
PROTAC CDK4/6 degrader-2 (50 nM; 3-24 h) begins to degrade CDK4 at 3 h in MCF-7 cells, with near-complete degradation by 24 h, whereas CDK6 is nearly completely degraded within 3 h[1].
PROTAC CDK4/6 degrader-2 (50 nM; 24 h; 3-48 h after washout) exhibits reversible and sustained CDK4/6 degradation in MCF-7 cells, with protein levels beginning to recover at 12 h after washout and returning to baseline levels at 24 h[1].
PROTAC CDK4/6 degrader-2 (50 nM; 24 h; pretreatment with MG132 (HY-13259) or Pomalidomide (HY-10984) at 10 μM for 6 h) induced CDK4/6 degradation is blocked by the proteasome inhibitor MG132 and attenuated by the CRBN ligand Pomalidomide, respectively, supporting that it mediates CDK4/6 degradation through CRBN recruitment and the ubiquitin-proteasome system[1].
PROTAC CDK4/6 degrader-2 (MCF-7: 10-40 nM; T47D: 50-150 nM; 24 h) dose-dependently induces G1 phase arrest and decreases RB phosphorylation, Cyclin D1, and c-MYC protein levels in MCF-7 and T47D cells[1].
PROTAC CDK4/6 degrader-2 (72 h) inhibits the growth of MCF-7 and T47D breast cancer cells with GI50 values of 10.09 nM and 72.02 nM, respectively; the GI50 for normal MCF-10A cells is 8.687 μM[1].
PROTAC CDK4/6 degrader-2 maintains growth inhibitory activity in Palbociclib (HY-50767)-resistant MCF-7 cells with a GI50 of 3.10 μM, whereas the GI50 values of Palbociclib and Dalpiciclib (HY-114338) rise to 16.80 μM and 19.40 μM, respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MCF-7
-
Concentration:50 nM
-
Incubation Time:24 h
-
Result:CDK4/6 protein levels began to recover 12 h after washout and returned to baseline by 24 h.
-
Cell Line:MCF-7
-
Concentration:50 nM
-
Incubation Time:3, 6, 12, 24 h
-
Result:Initiated CDK4 degradation at 3 h and achieved near-complete degradation by 24 h.
Almost completely degraded CDK6 within 3 h.
-
Cell Line:MCF-7
-
Concentration:PROTAC CDK4/6 degrader-2 50 nM; MG132 or Pomalidomide 10 μM
-
Incubation Time:Pretreatment 6 h; P11 24 h
-
Result:MG132 blocked P11-induced CDK4/6 degradation.
Pomalidomide attenuated PROTAC CDK4/6 degrader-2-induced CDK4/6 degradation.
-
Cell Line:MCF-7
-
Concentration:10, 20, 40 nM
-
Incubation Time:24 h
-
Result:Dose-dependently inhibited RB phosphorylation.
Reduced Cyclin D1 and c-MYC protein levels.
-
Cell Line:T47D
-
Concentration:50, 100, 150 nM
-
Incubation Time:24 h
-
Result:Dose-dependently inhibited RB phosphorylation.
Reduced Cyclin D1 and c-MYC protein levels.
Parmacokinetics
In Vivo
P11 (2-20 mg/kg; p.o.; i.v.) exhibits favorable pharmacokinetic properties in SD rats following both intravenous and oral administration[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude mice (female)[1]
-
Dosage:0.1 mmol/kg; 0.15 mmol/kg
-
Administration:p.o.; once daily; 18 days
-
Result:Markedly suppressed tumor growth in a dose-dependent manner and exhibited significantly greater inhibitory activity than dalpiciclib.
Inhibited tumor cell proliferation and promoted tumor cell death.
Markedly downregulated CDK4 and CDK6 protein levels, inhibited RB phosphorylation, and reduced cyclin D1 and c-MYC protein levels.
No significant changes in body weight were observed.
No apparent pathological abnormalities were revealed in the major organs.
Chemical Information
-
CAS No. 3135520-67-8
-
Masse moléculaire 855.00
-
Formule C47H54N10O6
-
SMILES
O=C1N(C(CC2)C(NC2=O)=O)C(C3=C1C=CC(N4CC(N5CCC(CN6CCC(C7=CC=C(NC8=NC=C(C(C)=C(C(C)=O)C(N9C%10CCCC%10)=O)C9=N8)N=C7)CC6)CC5)C4)=C3)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)